Table: Towa Pharmaceutical - 6-MTH group results
Nov 13 (Reuters)-
Towa Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2017 Sep 30, 2016 Mar 31, 2018
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 44.70 40.52 94.00
(+10.3 pct) (+3.5 pct) (+10.7 pct)
Operating 5.08 2.32 8.60
(+118.6 pct) (-57.9 pct) (+25.2 pct)
Recurring 6.06 383 mln 8.50
(-93.2 pct) (+14.6 pct)
Net 4.30 85 mln 5.80
(-97.9 pct) (+4.0 pct)
EPS 262.37 yen 5.21 yen 353.59 yen
EPS Diluted 242.62 yen 4.61 yen
Ann Div 95.00 yen 95.00 yen
-Q2 div 47.50 yen 47.50 yen
-Q4 div 47.50 yen 47.50 yen
NOTE - Towa Pharmaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4553.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on TOWA PHARMACEUTICAL
See all newsTable: Towa Pharmaceutical -Q1 group results
Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvals
Brief: Breckenridge Launches Tofacitinib Tablets, Generic Equivalent Of Xeljanz By Pfizer
Table: Towa Pharmaceutical -2025/26 parent results
Table: Towa Pharmaceutical -2025/26 group results